This article is more than 5 years old. Information may no longer be current.
VIDEO: ENDURANCE-1 shows 99% SVR in patients with HCV/HIV
Click Here to Manage Email Alerts
BOSTON — In this exclusive video from The Liver Meeting, Stefan Zeuzem, MD, chief of the department of medicine at the J.W. Goethe University Hospital in Frankfurt, Germany, discusses results of the ENDURANCE-1 clinical trial where a treatment regimen of glecaprevir/pibrentasvir (G/P) yielded high sustained virologic response rates in patients with hepatitis C genotype 1 after 8 weeks of treatment.
“It is fascinating to see that with just an 8-week therapy given once-daily, sustained virologic response rates of 99% were achieved.” Zeuzem said.
In the study, 351 patients with HCV genotype 1 without cirrhosis who were treatment-naive or failed therapy with previous interferon-based regimens were dosed with a pan-genotypic regimen of glecaprevir (ABT-493, AbbVie) plus pibrentasvir (ABT-530, AbbVie) for 8 or 12 weeks. This cohort also included patients with HIV-1 coinfection.
Overall, 99% of patients reached SVR12 after 8 weeks of treatment (n = 348).
“This is a robust, high efficacious, very safe and tolerable new regimen with short treatment duration,” Zeuzem said.
Disclosures: Zeuzem reports being a clinical investigator, consultant and speaker for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen and Merck.